AVITA Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on November 5, 2020, under Item 5.02 and reports a change in the Company’s senior finance leadership. The filing does not present quarterly or annual financial results.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating or financial metrics.
Material Changes
- Chief Financial Officer David McIntyre notified the Company of his resignation, effective November 23, 2020, to pursue life sciences opportunities in New Jersey.
- Mr. McIntyre agreed to provide consulting services through December 31, 2020, to support the transition.
- Sean Ekins, Vice President of Finance, will assume Mr. McIntyre’s responsibilities as principal financial officer and principal accounting officer effective November 9, 2020.
- The Company stated that it will immediately begin an external search for a permanent CFO based at its Valencia, California headquarters.
- The filing reports no family relationship or related-party transaction involving Mr. Ekins requiring disclosure under Item 404(a) of Regulation S-K.
Outlook, Risks, and Unusual Items
The principal disclosed risk is the transition in CFO and finance leadership while the Company conducts an external search for a permanent replacement. The filing does not provide management guidance or quantify any expected financial impact from the transition.
Investor Verification Items
- Confirm the effective dates of Mr. McIntyre’s resignation and Mr. Ekins’s assumption of finance responsibilities.
- Monitor the timing and qualifications of the permanent CFO appointment.
- Review subsequent filings for any changes to financial reporting, internal controls, liquidity, or other impacts associated with the leadership transition.